EGFR and gastroesophageal junction adenocarcinoma: We performed this meta-analysis of randomized trials to evaluate whether the addition of an anti-EGFR agent to chemotherapy can produce survival benefits in patients with advanced EAC, GAC, or gastroesophageal junction adenocarcinoma (GEJAC).